An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...

Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

Flagship Pioneering is leveraging its year-old London outpost to forge new research collaborations across the pond. | Flagship Pioneering is leveraging its year-old London outpost to forge new ...

As multisite clinical research corporations (MCRCs) proliferate to meet the increased demand for larger clinical trials that ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has tapped Katie Szyman for the role, who served as head of Edwards' critical ...

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. | The company’s cobas ...